Data presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phase 1 MYTHIC clinical trial treating patients with the combination of lunresertib, a first-in-class PKMYT1 inhibitor, and camonsertib, a potential best-in-class oral small molecule ATR inhibitor (lunre+camo).
“This individualized schedule in heavily pretreated patients with advanced cancers from our MYTHIC clinical trial met its goal of maintaining antitumor activity while reducing rates of grade 3 anemia,” said Maria Koehler, MD, PhD, Executive Vice President and Chief Medical Officer of Repare. “We believe that these data demonstrate a favorable and differentiated tolerability profile versus both current and emerging therapies. We look forward to sharing efficacy data from the gynecological cancer expansion cohort of the MYTHIC clinical trial in December 2024.”
Key Clinical Trial Findings:
- The individualized schedule mitigated mechanism-based anemia based on entry hemoglobin observed in a minority of patients
- Overall clinical benefit was maintained after schedule change with generally maintained radiographic regressions and molecular responses:
– Despite the change in schedule, deepening of target lesion regression was noted in some patients
– After 9 weeks on therapy, there was no observed impact on Progression Free Survival (PFS) in patients who started on or switched to the schedule of 2 weeks on / 1 week off of treatment - Dose optimization meaningfully reduced Grade 3 anemia (22.6% vs. 51.4%, previously) in all patients:
– Baseline marrow function was the key reason for Grade 3 anemia as opposed to exposure to therapy
– Baseline hemoglobin, prior therapies, and treatment intensity (weekly vs. 2 weeks on / 1 week off) predicted Grade 3 anemia frequency with lunre+camo
– Anemia reduction was greatest in patients with baseline hemoglobin less than 11g/dL (Grade 3 anemia at week 12: 34% vs. 68%, previously; overall risk reduction: 58%)
– Red blood cell transfusions (13% vs. 43%, previously), dose interruptions (13% vs. 23%) and dose reductions (6% vs. 17%) were also reduced with the new schedule
– Other Grade 3 events were already uncommon (Story continues belowAbout Repare Therapeutics Inc.
Forward-Looking Statements
Contacts
#distro
About Repare Therapeutics Inc.
Forward-Looking Statements
Contacts
#distro
Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.